Skip to main content

Cara Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 6, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 6, 2024

TVRD$1.410.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 6th day of March 2024.

​​​
​CARA THERAPEUTICS, INC.
​​
​By:/s/ CHRISTOPHER POSNER
​Name:Christopher Posner
​Title:President and Chief Executive Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Posner and Scott Terrillion, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution for him, and in his name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

​​​​​
SignatureTitleDate
​​​​​
/s/ CHRISTOPHER POSNER​President, Chief Executive Officer​March 6, 2024
Christopher Posner​(Principal Executive Officer)​​
​​​​​
/s/ RYAN MAYNARD​Chief Financial Officer​March 6, 2024
Ryan Maynard​(Principal Financial and Accounting Officer)​​
​​​​​
/s/ MARTIN VOGELBAUM​Director​March 6, 2024
Martin Vogelbaum​​​​
​​​​​
/s/ JEFFREY IVES​Director​March 6, 2024
Jeffrey Ives, Ph.D.​​​​
​​​​​
/s/ LISA VON MOLTKE​Director​March 6, 2024
Lisa von Moltke, M.D.​​​​
​​​​​
/s/ SUSAN SHIFF​Director​March 6, 2024
Susan Shiff, Ph.D.​​​​
​​​​​
/s/ HELEN BOUDREAU​Director​March 6, 2024
Helen Boudreau​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.